A laboratory-management view of what makes a test worth bringing in-house, where reference-laboratory turnaround time creates clinical friction, and how staffing, validation, integration, financing, and automation shape the final decision.
Audience: Laboratory Managers / Supervisors
Countries: 2
Completion Rate: 88.9%
SGID: 8979133
-Hero findings
– Quick Read — Key Findings
A send-out assay can look inexpensive on a spreadsheet until its turnaround time delays a treatment decision. An in-house assay can look strategically valuable until staffing, validation, analyzer capacity, LIS build, quality control, or utilization makes the service difficult to sustain.
The make-or-buy decision rarely belongs to one variable: clinical laboratories have to protect analytical quality while serving the timing, volume, and decision needs of the health system. In the United States, CLIA sets quality, personnel, proficiency-testing, and performance-verification requirements; internationally, ISO 15189:2022 frames medical-laboratory quality and competence as a management-system responsibility; and CLSI method-evaluation guidance expects new or modified methods to be validated or verified before routine patient testing.
The MDForLives survey asks laboratory leaders which testing categories they are considering for insourcing, what makes a test a strong candidate, where reference-lab turnaround creates the most friction, what metric drives the final decision, what blocks implementation, how platforms are financed, how send-outs are reassessed, who has the most influence, and what may reshape the model next.
62.5% say turnaround time and clinical impact have the greatest influence on the final in-house versus reference-laboratory decision, compared with 25.0% for cost per reportable result and 12.5% for test volume and utilization.
This reframes insourcing: the question is not simply whether the laboratory can run a test faster, but whether faster availability changes a care decision enough to justify the operational burden, which matters most when clinicians are waiting on a result to start, stop, narrow, or escalate treatment.
62.5% are evaluating molecular/PCR or syndromic infectious-disease testing for possible in-house expansion over the next 12-24 months. Routine chemistry/immunoassays or specialized immunology follows at 50.0%.
The prioritization aligns with where reference-lab turnaround is most often a problem, emergency/critical care and infectious disease/antimicrobial stewardship tie at 37.5%. That does not mean every molecular infectious-disease test should come in-house, but it shows why these assays attract attention when a delayed result has an immediate clinical workflow consequence.
50.0% say high volume with consistent demand is the primary factor that makes a test a strong in-house candidate, while 37.5% identify qualified laboratory staffing and expertise as the primary operational hurdle.
High volume with consistent demand
Clinically important TAT advantage
Qualified staffing and expertise hurdle
Validation or regulatory hurdle
The open responses make the trade-off concrete, respondents cite turnaround time, test cost, technologist time, rising order volume, instrument and supply cost, and the difficulty of keeping enough highly skilled microbiology staff, with one describing how financial pressure can overlook the impact on staff and patients. ASCP’s 2024 U.S. vacancy survey, published in 2025, describes persistent laboratory staffing shortages and slow hiring, external evidence that does not determine the result but helps explain why a technically attractive in-house service can stay operationally difficult.
Reagent rental or cost-per-test and direct capital purchase are tied at 37.5% each. Separately, 37.5% say send-out tests are reassessed at least annually.
Financing therefore looks flexible rather than standardized, and so does portfolio review: beyond the 37.5% who reassess at least annually, 25.0% review mainly when volume or clinical need changes, another 25.0% when cost or service issues arise, and 12.5% every two to three years.
75.0% say laboratory leadership has the greatest influence on major in-house versus reference-laboratory decisions. Looking ahead, 50.0% say automation and AI-enabled laboratory workflows are most likely to reshape the model over the next 3-5 years.
Leadership influence is appropriate because the decision crosses quality, staffing, technology, clinical service, and finance, yet laboratory leaders do not decide every part alone, a quarter identify multidisciplinary finance/operations teams as most influential, and many launch barriers sit in IT, capital planning, workforce strategy, or service-line workflow. ADLM’s 2026 policy work on AI in laboratory medicine emphasizes validation, interoperability, professional oversight, and monitoring, which matters because automation can lower manual burden or improve consistency but can also add a new implementation and governance layer.
The survey does not reduce insourcing to a cost calculation: turnaround time and clinical impact are the strongest decision metric, and high, consistent demand is the leading factor that makes a test attractive to run in-house, yet staffing is the largest single implementation hurdle and the open responses keep returning to technologist time, workforce availability, and operational cost. The opportunity and the constraint sit side by side.
So the most useful question may not be whether a laboratory can run a test here, but whether it can run it reliably enough, often enough, and fast enough to improve care without destabilizing the rest of the laboratory. Molecular infectious-disease testing stands out as a current priority, but the same logic applies across chemistry, immunoassays, oncology molecular testing, mass spectrometry, and other specialized services.
You have read the summary
Discover the complete research behind these insights, or become part of future studies with MDForLives.
Direct answers to common questions about insourcing tests, turnaround time, assay validation, financing, LIS/EHR integration, and laboratory automation.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
